David H. Crean’s Post

Some exciting data out from AusBiotech, quantifying the amount of capital from US investors flowing into Australian biotechs over five years between 2018-2022. The level of foreign investment coming into Australian biotech is a strong indicator of the industry’s growing position as a global leader. Data revealed in this report supports the fact that Australia’s biotech industry is becoming more attractive to international investors, and in turn, provides an evidence base to support targeted investment, policy and infrastructure that grows Australia’s life sciences ecosystem. As our inaugural foreign direct investment analysis, it will be exciting to track US investment over time and quantify investment from other key markets into Australian biotech. #biotechinvesting #biotechinvestment

🚀 Elevate Your Brand at BIO Europe 🌍 Are you ready to showcase your innovation to the world? 📈 The BIO Europe conference is a great stage for life science leaders, and One Nucleus is preparing the ON Helix Review for release at the conference. This could be the spotlight your company needs to shine brighter at BIO Europe and beyond. Prices start at just £500 + VAT for One Nucleus members. Why Sponsor the ON Helix Review? ✨ Unparalleled Visibility: Reach thousands of top-tier professionals and decision-makers in the international life sciences. ✨ Targeted Audience: Connect directly with your ideal customers, investors, and partners. ✨ Premium Placement: Stand out in a comprehensive review that attendees trust and reference. 📅 Don’t miss this golden opportunity to amplify your brand’s impact at one of the most influential events of the year. Secure your ad space now and be part of the conversation driving the future of life sciences. 🌟 Join us in transforming the future of life sciences and biotechnology. Your innovation deserves the spotlight! 🔗 Find out more here https://lnkd.in/eJ-TwrdB #BIOEurope #LifeSciences #Biotech #Innovation #Healthcare #BusinessGrowth #Marketing #Conference2024

New AusBiotech report shows increasing US investment in Australian biotechs Australia continues to attract significant #investment from US investors, with the total figure of US investment into Australian life science companies totaling US$1.43 billion and a strong growth trend over the five-year period, between 2018-2022. An analysis of investment data by AusBiotech shows 100 deals between US-based investors and Australian-headquartered life sciences companies over the analysis period.... Australian Trade and Investment Commission (Austrade) https://lnkd.in/gejXbJuu

An insightful free report by PwC on the UK Life Sciences Future50 company ecosystem💡🧬 Link to the report in the comments below👇🏽 #future50 #lifesciences #biotechnology #masonharding

Let’s join to explore the latest developments of the biotech industry at the HKEX Biotech Summit!

BIO-Europe is about to start in Munich! Managing Partner, Dr. Hubert Birner of TVM Capital Life Science talked about the dynamic changes in biotech investment, TVM's unique two-pronged strategy to investing in healthcare innovation, and the company's 20+ year relationship with BIO-Europe. Hear what he is looking forward to at this year's conference - and what he hopes will happen after this important event. Watch the full interview with his thoughtful commentary here: https://lnkd.in/gkfaraND #bioeurope2023

RESISTANCE IS NOT AN OPTION

Extremely topical #webinar today from Inpart ahead of #BIO2024 with helpful insights from J&J, especially on how #biotechs can improve both their outreach to and #partnering meetings with prospective #pharma #licensing partners. A few key points: 1. Focus on the science in your request for the meeting. 2. Clearly articulate how your science is novel and transformative, and the problem you're trying to solve. 3. Find a partner that shares your values. Look for a cultural fit that encourages a meaningful and long-term partnership.

 “While some are waiting for the IPO’s to come, there are a lot of interesting listed companies here today, you can invest in!”- Peter Legind-Hansen, Nasdaq The flagship indexes in the US are in all-time high and OMX Nordic is close to all time high despite a still little high interest rate and inflation. So, there IS a lot of money out there and the future and trends are looking brighter, yet there is still a lot of selectivity.  Already listed biotech and healthcare companies are more mature now and closer to reaching their ultimate goals but have much lower share prices than in 2021 due to the risk appetite and cost of capital. Two-day conference with Experts insights from international investors, successful dealmakers, Market Access experts – spiced with pitches from innovative Nordic biopharma companies – organized by BioStock - Connecting Innovation and Capital today and tomorrow. A conference connecting Nordic growth stage biopharma companies with global investors, expanding into new markets, creating global partnerships… We have a lot to offer and potential in the Nordic life science sector. Medicon Valley Alliance our mission is to strengthen our eco-system but also calling for increased collaboration within life science triple helix in the Nordics. Thank you to BioStock - Connecting Innovation and Capital for the invitation for these insightful days! HealthCap Agio Capital Sound Bioventures Sunstone Life Science Ventures Jonas Söderström

JUST DO IT 💪 15th of January is deadline for lower prices to join #CEBioForum2024 conference so if you know that you will be there anyway - listen to best advice mentioned above and DON'T WAIT 🤩 #biotech #business #cooperation #conference #networking